Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Clough Capital Partners Discloses 5.24% Stake In Veracyte Inc. (VCYT)

Moreover, Veracyte is on a good path towards creating a new diagnostic test that can surely unlock an additional revenue stream for the company. On May 20, Veracyte presented preliminary data that demonstrates the ability of the company’s molecular classifier to distinguish idiopathic pulmonary fibrosis (IPF) from other interstitial lung diseases (ILDs). Every single year in the U.S. and Europe, nearly 200,000 patients are suspected of suffering from an ILD, including IPF that is considered as the most common, deadly and difficult to diagnose. Leaving the terminology behind, the innovative power of Veracyte will not only generate strong future financial performance, but will also save thousands of lives worldwide. According to some scientists and officials at Veracyte, the recently published results take the company a step closer to creating a diagnostic test that could help numerous patients.

Moving on to the financial performance of Veracyte, the company delivered strong financial results during the first quarter of the year. The company generated revenues of $11.2 million during the quarter, which marks an increase of 50% year-over-year. The strong revenues were mainly enhanced by the commercial momentum of its Afirma GEC diagnostic tests, which were reported to reach a number of 4,020 at the end of the quarter compared to 3,098 during the first quarter a year ago. Despite the fact that the company reported a net loss of $0.34 per share, higher than the $0.32 figure for the same period in 2014, Veracyte is on a good run lately and the stock might keep rising in the upcoming months and years.

Mitchell Blutt’s Consonance Capital Management and Israel Englander’s Millennium Management are some of the largest shareholders in Veracyte Inc. (NASDAQ:VCYT) in our database, owning 235,860 shares and 196,611 shares, respectively.

 Disclosure: None

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.